港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

生物醫藥B類股

437.197

+6.7341.56%

漲家數：13

跌家數：17

平家數：4

市盈率：- -

高：444.607

開：430.463

低：424.474

收：430.463

資料載入中...

科濟藥業-B盤中異動下午盤急速上漲5.00%報15.960港元

華東醫藥：公司與科濟藥業合作進行商業化的賽愷澤產品目前市場拓展順利

和鉑醫藥-B盤中異動股價大漲5.02%報6.280港元

徐冠巨代表：及時修訂《國民經濟行業分類》，納入新興產業

和鉑醫藥-B盤中漲超4% 收到Windward Bio授權協議首付款

港股異動 | 德琪醫藥-B(06996)漲超14% 公司計劃加大AI藥物研發投入希維奧®在印度尼西亞獲批上市

和鉑醫藥簽署獨家協議收到相應首付款

港股異動 | 和鉑醫藥-B(02142)漲超4% 收到Windward Bio授權協議首付款全年現金利潤達2.2億元

AI賦能製藥行業，推動藥物研發和臨牀試驗雙重突破

港股創新藥ETF漲超2.5%，來凱醫藥-B漲超11%，機構：具有高科技屬性的醫藥醫療公司將更受市場青睞

21世纪经济报道

康方生物(09926.HK)卡度尼利治療高復發風險肝細胞癌三期臨牀完成患者入組

阿斯达克财经

港股異動 | 歌禮制藥-B(01672)漲超5% ASC30、ASC47均具備差異化設計方式產品發展未來可期

歌禮制藥-B盤中異動股價大漲5.14%

中國抗體-B盤中異動股價大漲6.19%報1.200港元

諾誠健華盤中異動早盤股價大漲5.05%

加科思-B盤中異動早盤股價大漲5.32%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1574/news?page=8"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":437.19687,"timestamp":1741334919603,"preClose":430.4633,"halted":0,"volume":156813444,"delay":0,"changeRate":0.015643,"change":6.733582,"pbRate":3.43319,"amount":2812448156,"amplitude":0.046771,"prevYearClose":331.1933,"fiveDayClose":411.011,"twentyDayClose":335.39,"turnoverRate":0.005967,"marketCap":244193759232,"floatMarketCap":230149584960,"peRate":-17.305245},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":444.6071,"amplitude":0.046771,"preClose":430.4633,"low":424.47403,"pbRate":"3.43319","latestPrice":437.19687,"volume":156813444,"delay":0,"open":430.4633,"prevYearClose":331.1933,"prevWeekClose":411.011,"prevMonthClose":411.011,"prevQuarterClose":331.193,"fiveDayClose":411.011,"twentyDayClose":335.39,"sixtyDayClose":340.535,"secType":"PLATE","market":"HK","turnoverRate":0.005967,"peRate":-17.305245,"marketCap":244193759232,"floatMarketCap":230149584960,"timestamp":1741334919603,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":13,"down":17,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:16,pageCount:8,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517318854","title":"科濟藥業-B盤中異動 下午盤急速上漲5.00%報15.960港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517318854","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517318854?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 13:11","pubTimestamp":1741237872,"startTime":"0","endTime":"0","summary":"2025年03月06日下午盘13时11分，科济药业-B股票出现异动，股价快速拉升5.00%。截至发稿，该股报15.960港元/股，成交量434.15万股，换手率0.76%，振幅5.00%。科济药业-B股票所在的生物技术行业中，整体涨幅为0.35%。2月26日，科济药业公告披露，旗下优恺泽生物完成珠海软银主导的8000万元战略融资，对应估值达10亿元。科济药业的转型之路颇具行业启示意义。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306131112963baef8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306131112963baef8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1587","BK1161","BK1585","02171"],"gpt_icon":0},{"id":"2517188360","title":"華東醫藥：公司與科濟藥業合作進行商業化的賽愷澤 產品目前市場拓展順利","url":"https://stock-news.laohu8.com/highlight/detail?id=2517188360","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517188360?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 13:04","pubTimestamp":1741237440,"startTime":"0","endTime":"0","summary":"登录新浪财经APP 搜索【信披】查看更多考评等级\n　　证券之星消息，华东医药(000963)03月05日在投资者关系平台上答复投资者关心的问题。　　投资者：贵公司今后还有没有和科济药业继续合作的项目？　　华东医药董秘：您好！公司与科济药业合作进行商业化的赛恺泽产品目前市场拓展顺利。今后公司如有进一步的对外合作计划，将按照信息披露相关规定及时公告。感谢您的关注！\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-03-06/doc-inenswir0946806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","BK0175","LU1969619763.USD","BK1161","BK1585","BK1574","LU2328871848.SGD","000963","02171","BK0196","BK1587","BK0183","BK0187","BK0209","BK0132"],"gpt_icon":0},{"id":"2517076419","title":"和鉑醫藥-B盤中異動 股價大漲5.02%報6.280港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517076419","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517076419?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 13:01","pubTimestamp":1741237292,"startTime":"0","endTime":"0","summary":"2025年03月06日下午盘13时01分，和铂医药-B股票出现波动，股价快速上涨5.02%。截至发稿，该股报6.280港元/股，成交量660.5万股，换手率0.87%，振幅4.68%。资金方面，该股资金流入1951.4万港元，流出1642.73万港元。和铂医药-B股票所在的生物技术行业中，整体涨幅为0.35%。其相关个股中，迈博药业-B、创胜集团-B、帝王国际投资涨幅较大，振幅较大的相关个股有迈博药业-B、帝王国际投资、创胜集团-B，振幅分别为75.76%、48.28%、24.84%。该公司的产品包括HBM9161, HBM4003, HBM7008 and HBM1020。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306130132a261db10&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306130132a261db10&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","BK1583","02142"],"gpt_icon":0},{"id":"2517904166","title":"徐冠巨代表：及時修訂《國民經濟行業分類》，納入新興產業","url":"https://stock-news.laohu8.com/highlight/detail?id=2517904166","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517904166?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 12:32","pubTimestamp":1741235521,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["300832","BK1574","BK1515","BK0239","159938","BK1161","09939"],"gpt_icon":0},{"id":"2517093909","title":"和鉑醫藥-B盤中漲超4% 收到Windward Bio授權協議首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2517093909","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517093909?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 11:50","pubTimestamp":1741233000,"startTime":"0","endTime":"0","summary":"　　和铂医药-B盘中涨超4%，截至发稿，股价上涨3.34%，现报6.18港元，成交额3817.96万港元。　　和铂医药宣布，根据其与科伦博泰就HBM9378/SKB378与Windward Bio AG签订的许可协议，公司已收到相应首付款，包括现金付款及Windward Bio母公司股权。根据2025年1月10日签订的许可协议，Windward Bio获得HBM9378/SKB378在全球范围内进行研究、开发、生产和商业化的独家授权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-06/doc-inensrzp6938284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1161","02142","BK1583"],"gpt_icon":0},{"id":"2517990939","title":"港股異動 | 德琪醫藥-B(06996)漲超14% 公司計劃加大AI藥物研發投入 希維奧®在印度尼西亞獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2517990939","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517990939?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 11:33","pubTimestamp":1741231981,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，德琪医药-B涨超14%，该股年内累计涨幅达390%。截至发稿，涨14.18%，报3.22港元，成交额1496.4万港元。消息面上，德琪医药昨日宣布，印度尼西亚食品药品监督管理局已批准希维奥的新药上市申请。值得一提的是，今年2月，德琪医药宣布计划加大投入，整合资源成立专门的AI部门。据悉，公司早在2021年便以天使投资人身份投资杭州德睿智药AI药物发现平台，并借此战略性的切入了AI药物发现赛道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258407.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1574","06996","BK1583"],"gpt_icon":0},{"id":"2517390640","title":"和鉑醫藥簽署獨家協議 收到相應首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2517390640","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517390640?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 11:19","pubTimestamp":1741231199,"startTime":"0","endTime":"0","summary":"3月6日，和铂医药-B（02142）发布公告，公司已根据与WindwardBioAG签署的独家授权协议，收到相应的首付款，包括现金付款及WindwardBio母公司的股权。此首付款的到账将进一步增强公司的现金储备。根据公告，协议于2025年1月10日签署，合作方包括四川科伦博泰生物医药股份有限公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503063338318139.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1574","02142","BK1161"],"gpt_icon":0},{"id":"2517903694","title":"港股異動 | 和鉑醫藥-B(02142)漲超4% 收到Windward Bio授權協議首付款 全年現金利潤達2.2億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517903694","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517903694?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 10:38","pubTimestamp":1741228712,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B涨超4%，截至发稿，涨4.52%，报6.25港元，成交额2454.87万港元。消息面上，和铂医药宣布，根据其与科伦博泰就HBM9378/SKB378与Windward Bio AG签订的许可协议，公司已收到相应首付款，包括现金付款及Windward Bio母公司股权。此前，和铂医药发盈喜，预期截至2024年12月31日止年度的溢利将介于人民币730万元至2200万元。期内，公司的现金溢利达到人民币2.20亿元的历史新高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1574","02142","BK1161"],"gpt_icon":0},{"id":"2517905640","title":"AI賦能製藥行業，推動藥物研發和臨牀試驗雙重突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2517905640","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517905640?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 10:37","pubTimestamp":1741228623,"startTime":"0","endTime":"0","summary":"随着人工智能技术的快速发展，AI制药行业正在迎来重要的技术突破与应用落地。AI技术，尤其是深度学习和数据分析的应用，正在重塑制药行业的研发模式，提升药物发现与开发的效率。从传统的药物研发流程来看，AI的介入使得药物筛选、临床试验设计、药物合成等环节变得更加高效且精准，显著降低了研发成本和时间。","market":"hk","thumbnail":"https://images.finet.hk/photoLib/title/202503_1/65534541-ee94-45a6-9ad3-850346f6c9f8.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202503_1/65534541-ee94-45a6-9ad3-850346f6c9f8.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/67c90a4f5a77124484e680e1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["BK1191","01477","03347","BK1141","BK1583","BK1576","BK1574"],"gpt_icon":0},{"id":"2517055799","title":"港股創新藥ETF漲超2.5%，來凱醫藥-B漲超11%，機構：具有高科技屬性的醫藥醫療公司將更受市場青睞","url":"https://stock-news.laohu8.com/highlight/detail?id=2517055799","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517055799?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 10:35","pubTimestamp":1741228542,"startTime":"0","endTime":"0","summary":"相关ETF方面，港股创新药ETF截至发稿涨2.52%，成交额超1亿元，换手率超20%，盘中交投活跃。港股创新药ETF紧密跟踪港股通创新药指数，该指数反映港股通生物科技产业上市公司的运行特征。财通证券表示，看多创新药政策新周期带来的产业链共振上升，看多AI对医药产业带来的中长期影响，具有高科技属性的医药医疗公司将更受市场青睐。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306104204a261a137&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306104204a261a137&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105","09939","BK1574","BK1515"],"gpt_icon":0},{"id":"2517039419","title":"康方生物(09926.HK)卡度尼利治療高復發風險肝細胞癌三期臨牀完成患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2517039419","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517039419?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 10:33","pubTimestamp":1741228380,"startTime":"0","endTime":"0","summary":"康方生物宣布，自主研发的全球首创PD-1/CTLA-4双抗新药卡度尼利“开坦尼”，用于高复发风险肝细胞癌根治术或消融后辅助治疗的注册性三期临床研究，近日已完成全部患者入组。目前卡度尼利配合仑伐替尼和经肝动脉化疗栓塞用于治疗中晚期不可切除HCC的注册三期临床研究也在进行中，公司预期，卡度尼利可望成为早期和中晚期HCC患者全方位且更有效率的疾病解决方案。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230531145638513_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230531145638513_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1422587/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0417516571.SGD","BK1161","IE00B543WZ88.USD","LU0348784397.USD","IE00BPRC5H50.USD","09926","LU0348783233.USD","BK1574","LU2488822045.USD","LU1720050803.USD","IE00B5MMRT66.SGD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2517908031","title":"港股異動 | 歌禮制藥-B(01672)漲超5% ASC30、ASC47均具備差異化設計方式 產品發展未來可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2517908031","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517908031?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 10:22","pubTimestamp":1741227746,"startTime":"0","endTime":"0","summary":"中信建投发布研报称，歌礼制药-B发布公告，其GLP-1R激动剂ASC30在美国Ib期临床试验取得积极成果。数据显示，前两个列队中ASC30经安慰剂组校准后分别使体重下降4.2%和6.2%，并且安全性良好。该行认为，全球减重药物市场规模蓬勃成长，众多超重或肥胖成年人群急需创新药物来改善并提高生活质量，在此基础下，公司的两款药物ASC30、ASC47均具备差异化设计方式，产品发展未来可期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258377.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01477","BK1515","BK1161","01672","BK1191"],"gpt_icon":0},{"id":"2517908542","title":"歌禮制藥-B盤中異動 股價大漲5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517908542","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517908542?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 10:19","pubTimestamp":1741227599,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘10时19分，歌礼制药-B股票出现波动，股价急速上涨5.14%。截至发稿，该股报7.360港元/股，成交量325.1万股，换手率0.34%，振幅5.29%。资金方面，该股资金流入953.631万港元，流出1142.22万港元。歌礼制药-B股票所在的生物技术行业中，整体涨幅为2.00%。该公司主要专注于病毒性疾病、非酒精性脂肪性肝炎及肿瘤领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306102000a261980a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306102000a261980a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1191","BK1515","01477","01672","BK1574"],"gpt_icon":0},{"id":"2517035289","title":"中國抗體-B盤中異動 股價大漲6.19%報1.200港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517035289","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517035289?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 10:03","pubTimestamp":1741226617,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘10时03分，中国抗体-B股票出现异动，股价快速上涨6.19%。截至发稿，该股报1.200港元/股，成交量11.73万股，换手率0.01%，振幅6.19%。资金方面，该股资金流入12.8622万港元，流出1.1202万港元。中国抗体-B股票所在的生物技术行业中，整体涨幅为2.26%。中国抗体-B公司简介：中国抗体制药有限公司是一家主要研究、发展、制造及商业化免疫性疾病疗法的中国香港生物制药公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306100337963b8092&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306100337963b8092&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","03681"],"gpt_icon":0},{"id":"2517970556","title":"諾誠健華盤中異動 早盤股價大漲5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517970556","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517970556?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 09:59","pubTimestamp":1741226393,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘09时59分，诺诚健华股票出现异动，股价快速上涨5.05%。截至发稿，该股报9.980港元/股，成交量189.5万股，换手率0.13%，振幅5.05%。机构评级方面，在所有9家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。诺诚健华股票所在的生物技术行业中，整体涨幅为2.31%。其相关个股中，复宏汉霖、加科思-B、昭衍新药涨幅较大，振幅较大的相关个股有创胜集团-B、复宏汉霖、腾盛博药-B，振幅分别为11.18%、10.36%、10.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306095953abea7a1b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306095953abea7a1b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688428","BK1161","09969","BK1574"],"gpt_icon":0},{"id":"2517970891","title":"加科思-B盤中異動 早盤股價大漲5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517970891","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517970891?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 09:57","pubTimestamp":1741226263,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘09时57分，加科思-B股票出现异动，股价急速上涨5.32%。截至发稿，该股报2.770港元/股，成交量334.23万股，换手率0.42%，振幅5.70%。加科思-B股票所在的生物技术行业中，整体涨幅为2.17%。其相关个股中，腾盛博药-B、复宏汉霖、宜明昂科-B涨幅较大，振幅较大的相关个股有创胜集团-B、腾盛博药-B、贝康医疗-B，振幅分别为11.18%、9.39%、9.38%。公司主要药物开发项目包括JAB-3068及JAB-3312临床阶段的变构SHP2抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306095743abea7927&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306095743abea7927&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01167","BK1161","BK1574"],"gpt_icon":0}],"pageSize":16,"totalPage":45,"pageCount":8,"totalSize":708}]}}